At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 154 enrolled
Drug / intervention
tenofovir DF 300 mg QD +6 moredrug
Likely dose
tenofovir DF 300 mg QDfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison Atazanavir/Ritonavir (ATV/r) vs Nevirapine (NVP) Twice a Day (Bid) on Truvada Backbone
In Brief
A Phase 4 clinical trial evaluating tenofovir DF 300 mg QD, emtricitabine 200 mg QD, and 3 other interventions for HIV Infections. Completed, enrolled 154 participants across 19 sites.
Detailed Summary
The aim of this clinical trial is to compare the efficacy and safety of ritonavir (RTV)-boosted atazanavir with nevirapine, each on a background of emtricitabine and tenofovir disoproxil fumarate (DF).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
First PostedNov 2007
Primary CompletionMar 2010
TodayJul 2026
First PostedNov 1, 2007
Enrollment StartSep 1, 2007
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.7 years ago
Interventions
tenofovir DF 300 mg QDdrug
300 mg QD
tenofovir DF 300 mg QDdrug
300 mg QD
emtricitabine 200 mg QDdrug
200 mg QD
emtricitabine 200 mg QDdrug
200 mg QD
Nevirapine 200 mg BIDdrug
200 mg BID
Atazanavir 300 mgdrug
300 mg QD
Ritonavir 100 mgdrug
100 mg QD